Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Georgios Schoretsanitis, Jonathan M. Meyer, Andreas Conca & Christoph Hiemke. (2023) Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations. Expert Opinion on Drug Metabolism & Toxicology 19:4, pages 189-202.
Read now
Read now
Wagner F Gattaz, Ricardo Saracco-Alvarez, Claudiane Salles Daltio, Martinus T Van de Bilt, Jose Julian Ortegón, Sergio J Villaseñor-Bayardo, Mario Louzã, Helio Elkis, Bernardo Soares, Patricia Cabrera Jaramillo, Fabio Lawson & Leonardo Díaz-Galvis. (2020) Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability. Neuropsychiatric Disease and Treatment 16, pages 2063-2072.
Read now
Read now
Maju Mathews, Srihari Gopal, Isaac Nuamah, Ludger Hargarter, Adam J Savitz, Edward Kim, Wilson Tan, Bernardo Soares & Christoph U Correll. (2019) Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1365-1379.
Read now
Read now
LiLi Zhang, JiTao Li, YanJie Zhao, Yun’Ai Su & Tianmei Si. (2016) Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review. Neuropsychiatric Disease and Treatment 12, pages 113-131.
Read now
Read now
Tianmei Si, Kerang Zhang, Jisheng Tang, Maosheng Fang, Keqing Li, Jianmin Zhuo & Yu Feng. (2015) Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study. Neuropsychiatric Disease and Treatment 11, pages 1483-1492.
Read now
Read now
Srihari Gopal, An Vermeulen, Partha Nandy, Paulien Ravenstijn, Isaac Nuamah, José Antonio Buron Vidal, Joris Berwaerts, Adam Savitz, David Hough & Mahesh N. Samtani. (2015) Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Current Medical Research and Opinion 31:11, pages 2043-2054.
Read now
Read now
Mahesh N Samtani, Isaac Nuamah, Srihari Gopal, Bart Remmerie, Jennifer Kern Sliwa & Larry Alphs. (2013) Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose. Neuropsychiatric Disease and Treatment 9, pages 721-730.
Read now
Read now
Larry Alphs, Cynthia A Bossie, Jennifer Kern Sliwa, Dong-Jing Fu, Yi-Wen Ma & Joseph Hulihan. (2013) Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. Neuropsychiatric Disease and Treatment 9, pages 341-350.
Read now
Read now
Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthoj, Wagner F. Gattaz, Florence Thibaut & Hans-Jürgen Möller. (2013) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. The World Journal of Biological Psychiatry 14:1, pages 2-44.
Read now
Read now
Shiyun Kim, Hugo Solari, Peter J Weiden & Jeffrey R Bishop. (2012) Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. Patient Preference and Adherence 6, pages 533-545.
Read now
Read now
Pierre Chue & James Chue. (2012) A review of paliperidone palmitate. Expert Review of Neurotherapeutics 12:12, pages 1383-1397.
Read now
Read now
Ofer Agid, George Foussias & Gary Remington. (2010) Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opinion on Pharmacotherapy 11:14, pages 2301-2317.
Read now
Read now
Articles from other publishers (43)
Shuai Yu, Zihao Wang, Panpan Yu, Shanshan Wang, Guangzhou Li, Fumin Xue & Long Fu. (2023) Solid-liquid phase equilibrium and thermodynamic properties analysis of paliperidone palmitate in 21 kinds of mono-solvents. The Journal of Chemical Thermodynamics 181, pages 107033.
Crossref
Crossref
Heidi Taipale, Antti Tanskanen, Jurjen J Luykx, Marco Solmi, Stefan Leucht, Christoph U Correll & Jari Tiihonen. (2022) Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. Schizophrenia Bulletin 48:4, pages 774-784.
Crossref
Crossref
Georgios Schoretsanitis, Ekkehard Haen, Daria Piacentino, Andreas Conca, Katharina Endres, Fabio Carpi, Christoph Hiemke, Gerhard Gründer & Michael Paulzen. (2021) Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. Clinical Pharmacokinetics 60:12, pages 1583-1589.
Crossref
Crossref
Michael Ming Cheuk Wong, Albert Kar Kin Chung, Timothy Ming Hong Yeung, David Tai Wai Wong, Che Kin Lee, Eric Lai, Gloria Fong Yeung Chan, Gregory Kai Lok Mak, Jessica Oi Yin Wong, Roger Man Kin Ng & Ki Yan Mak. (2021) Guidance on the clinical understanding and use of long‐acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements. CNS Neuroscience & Therapeutics 27:S1, pages 5-11.
Crossref
Crossref
Georgios SchoretsanitisPierre BaumannAndreas ConcaOtto DietmaierGiancarlo GiupponiGerhard GründerMartina HahnXenia HartUrsula Havemann-ReineckeGudrun HefnerMaxim KuzinRainald MössnerDaria PiacentinoWerner SteimerGerald Zernig & Christoph Hiemke. (2021) Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. Therapeutic Drug Monitoring 43:1, pages 79-102.
Crossref
Crossref
Maytinee Srifuengfung, Thanisorn Sukakul, Chanika Liangcheep & Natee Viravan. (2020) Paliperidone palmitate-induced facial angioedema: A case report. World Journal of Clinical Cases 8:20, pages 4876-4882.
Crossref
Crossref
Anna Ceraso, Jessie Jingxia LIN, Johannes Schneider-Thoma, Spyridon Siafis, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, John M Davis & Stefan Leucht. (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2020:8.
Crossref
Crossref
Stefan LeuchtAlessio CrippaSpyridon SiafisMaxine X. PatelNicola OrsiniJohn M. Davis. (2020) Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. American Journal of Psychiatry 177:4, pages 342-353.
Crossref
Crossref
Fabrice Berna, Anja S. Göritz, Guillaume Behr & Steffen Moritz. (2020) Pill or needle? Determinants of the preference for long-acting injection over oral treatment in people facing chronic illness. Progress in Neuro-Psychopharmacology and Biological Psychiatry 98, pages 109798.
Crossref
Crossref
Hiroko Shimizu, Martine Neyens, Marc De Meulder, Srihari Gopal, Yuko Tsukamoto, Mahesh N. Samtani & Bart Remmerie. (2019) Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia. Clinical Pharmacology in Drug Development 9:2, pages 224-234.
Crossref
Crossref
So-Young Oh, Duk-In Jon, Hyun Ju Hong, Narei Hong, Jung-Seo Yi, Daeyoung Roh & Myung Hun Jung. (2019) The Impact of Paliperidone Palmitate on Hospitalization in Patients with Schizophrenia: A Retrospective Mirror-image Study. Clinical Psychopharmacology and Neuroscience 17:4, pages 531-536.
Crossref
Crossref
Alberto Russu, Adam Savitz, Maju Mathews, Srihari Gopal, Yu Feng & Mahesh N. Samtani. (2019) Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations. Journal of Clinical Psychopharmacology 39:6, pages 567-574.
Crossref
Crossref
Lee M. Tatham, Neill J. Liptrott, Steve P. Rannard & Andrew Owen. (2019) Long-Acting Injectable Statins—Is It Time for a Paradigm Shift?. Molecules 24:15, pages 2685.
Crossref
Crossref
Chengyue Guo, Yanna Chen, Junzhe Zhu, Jiaxin Wang, Ying Xu, Hansen Luan & Hao Wang. (2018) Optimization of Extended-Release ZL-004 Nanosuspensions for In Vivo Pharmacokinetic Study to Enhance Low Solubility and Compliance. Molecules 24:1, pages 7.
Crossref
Crossref
Alirez Ranaei & Shahriar Najafizadeh-Sari. (2018) Anti-Depressant Effects of Palmitic Acid: The Necessity of Focusing on New Agents. International Journal of Medical Reviews 4:4, pages 93-94.
Crossref
Crossref
Alberto Russu, Jennifer Kern Sliwa, Paulien Ravenstijn, Arun Singh, Maju Mathews, Edward Kim & Srihari Gopal. (2018) Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations. International Journal of Clinical Practice 72:6, pages e13089.
Crossref
Crossref
Zengliu Su, Christina Overton, Frank Wallace & Gregory McIntire. (2017) Positive Urine Paliperidone Test Results in the Absence of Prescribed Medication. The Journal of Applied Laboratory Medicine 2:3, pages 436-439.
Crossref
Crossref
Seoyoung Jang & Jungmin Woo. (2017) Five Month-Persistent Extrapyramidal Symptoms following a Single Injection of Paliperidone Palmitate: A Case Report. Clinical Psychopharmacology and Neuroscience 15:3, pages 288-291.
Crossref
Crossref
Erdinc Cicek, Ismet Esra Cicek & Faruk Uguz. (2017) Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report. Clinical Psychopharmacology and Neuroscience 15:2, pages 184-186.
Crossref
Crossref
Mats O. Magnusson, Mahesh N. Samtani, Elodie L. Plan, E. Niclas Jonsson, Stefaan Rossenu, An Vermeulen & Alberto Russu. (2017) Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data. CNS Drugs 31:4, pages 273-288.
Crossref
Crossref
Mahesh N. Samtani, Partha Nandy, Paulien Ravenstijn, Bart Remmerie, An Vermeulen, Alberto Russu, Peter D'hoore, Ellen Z. Baum, Adam Savitz, Srihari Gopal & David Hough. (2016) Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy. British Journal of Clinical Pharmacology 82:5, pages 1364-1370.
Crossref
Crossref
Andrew Owen & Steve Rannard. (2016) Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. Advanced Drug Delivery Reviews 103, pages 144-156.
Crossref
Crossref
Javier Quintero, Itziar Oyagüez, Beatriz González, Ignacio Cuervo-Arango, Ignacio García & Miguel Angel Casado. (2016) Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain. Clinical Drug Investigation 36:6, pages 479-490.
Crossref
Crossref
Masakazu Hatano, Hiroyuki Kamei & Nakao Iwata. (2016) The role of long-acting injection in schizophrenia treatment and future challenges. Drug Delivery System 31:3, pages 186-193.
Crossref
Crossref
Michael W. Jann & W. Klugh Kennedy. 2016. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
139
175
.
Nerea Palomares, Ana Montes, Marina Díaz-Marsá & José L. Carrasco. (2015) Effectiveness of long-acting paliperidone palmitate in borderline personality disorder. International Clinical Psychopharmacology 30:6, pages 338-341.
Crossref
Crossref
A Schreiner, P Bergmans, P Cherubin, S Keim, P-M Llorca, B Cosar, A Petralia, G Corrivetti & L Hargarter. (2015) Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. Journal of Psychopharmacology 29:8, pages 910-922.
Crossref
Crossref
Elaine Merisko-Liversidge. 2015. Discovering and Developing Molecules with Optimal Drug-Like Properties. Discovering and Developing Molecules with Optimal Drug-Like Properties
437
467
.
Donglei Leng, Hongming Chen, Guangjing Li, Mengran Guo, Zhaolu Zhu, Lu Xu & Yongjun Wang. (2014) Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size. International Journal of Pharmaceutics 472:1-2, pages 380-385.
Crossref
Crossref
Adriaan Cleton, Stefaan Rossenu, Herta Crauwels, Joris Berwaerts, David Hough, Srihari Gopal, Marielle Eerdekens, An Vandebosch, Bart Remmerie, Marc De Meulder & Clara M. Rosso Fernández. (2014) A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. The Journal of Clinical Pharmacology 54:9, pages 1048-1057.
Crossref
Crossref
Tianmei Si, Yun'ai Su, Yi Liu, Hongyan Zhang, Huafang Li, Qing Rui & Liang Shu. (2014) Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjects. Human Psychopharmacology: Clinical and Experimental 29:2, pages 203-210.
Crossref
Crossref
A. G. Sofronov, A. A. Spikina & Iu. A. Parfenov. (2014) Indicators of treatment of schizophrenia in different stages of psychiatric care. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 114:11. Vyp. 2, pages 22.
Crossref
Crossref
Anja Cerovecki, Richard Musil, Ansgar Klimke, Florian Seemüller, Ekkehard Haen, Rebecca Schennach, Kai-Uwe Kühn, Hans-Peter Volz & Michael Riedel. (2013) Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations. CNS Drugs 27:7, pages 545-572.
Crossref
Crossref
Danielle Coppola, Yanning Liu, Srihari Gopal, Bart Remmerie, Mahesh N Samtani, David W Hough, Isaac Nuamah, Ahmad Sulaiman & Gahan Pandina. (2012) A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry 12:1.
Crossref
Crossref
Nga Tran & Deirdre Alderton. 2012. Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition. Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition
1
31
.
David J. Castle, Nga Tran & Deirdre Alderton. 2012. Pharmacological and Psychosocial Treatments in Schizophrenia. Pharmacological and Psychosocial Treatments in Schizophrenia
1
31
.
Natalie J. Carter. (2012) Extended-Release Intramuscular Paliperidone Palmitate. Drugs 72:8, pages 1137-1160.
Crossref
Crossref
Kevin Quinn, Rampurna Prasad Gullapalli, Elaine Merisko-liversidge, Erich Goldbach, Angelina Wong, Gary G. Liversidge, Wherly Hoffman, John-michael Sauer, John Bullock & George Tonn. (2012) A Formulation Strategy for Gamma Secretase Inhibitor ELND006, a BCS Class II Compound: Development of a Nanosuspension Formulation with Improved Oral Bioavailability and Reduced Food Effects in Dogs. Journal of Pharmaceutical Sciences 101:4, pages 1462-1474.
Crossref
Crossref
Cynthia A Bossie, Jennifer K Sliwa, Yi-Wen Ma, Dong-Jing Fu & Larry Alphs. (2011) Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry 11:1.
Crossref
Crossref
Jennifer Kern Sliwa, Cynthia A. Bossie, Yi-Wen Ma & Larry Alphs. (2011) Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophrenia Research 132:1, pages 28-34.
Crossref
Crossref
Cynthia A. Bossie, Dong-Jing Fu, Jennifer Kern Sliwa, Larry Alphs & Yi-Wen Ma. (2011) Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. Therapeutic Advances in Psychopharmacology 1:4, pages 111-124.
Crossref
Crossref
Elaine Merisko-Liversidge & Gary G. Liversidge. (2011) Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology. Advanced Drug Delivery Reviews 63:6, pages 427-440.
Crossref
Crossref
Larry Alphs, Cynthia A Bossie, Jennifer K Sliwa, Yi-Wen Ma & Norris Turner. (2011) Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Annals of General Psychiatry 10:1, pages 12.
Crossref
Crossref